Akashi Therapeutics, Inc. Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Akashi Therapeutics is a clinical-stage biotechnology company focused on developing therapies for Duchenne muscular dystrophy and other rare diseases. Its lead program, HT-100, targets fibrosis and inflammation while supporting healthy muscle regeneration, and a second candidate, DT-200, is a selective androgen receptor modulator aimed at increasing muscle mass and strength. The company traces its origins to a collaboration between Halo Therapeutics and Dart Therapeutics, formed with input from patient advocacy groups and biotechnology veterans, and it is guided by a team experienced in drug development. 

Based in Cambridge, Massachusetts, Akashi operates as a small biotechnology team within the research sector. Its focus is on therapies for Duchenne muscular dystrophy and other rare pediatric diseases. In 2019, Akashi entered into an exclusive worldwide license with Processa Pharmaceuticals to develop and commercialize HT-100, reflecting early collaboration with external partners.

Sign up for free to view info

Company overview Employee directory